VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL

Oncology Research

Volumn 18, Issue 2-3, 2009, Pages 117-125

  Guan, Hui ^a   Zhou, Zhichao ^a   Cao, Ying ^a   Duan, Xiaoping ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ewing's sarcoma; Osteolysis; RANKL; VEGF165

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BETA ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN 165; ACTIN BINDING PROTEIN; CELL RECEPTOR; FLII PROTEIN, HUMAN; RNA BINDING PROTEIN EWS; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CONTROLLED STUDY; EWING SARCOMA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; STAINING; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICROFILAMENT PROTEINS; OSTEOCLASTS; OSTEOLYSIS; PROMOTER REGIONS, GENETIC; RANK LIGAND; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA-BINDING PROTEIN EWS; SARCOMA, EWING'S; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75649112276     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504009789954627     Document Type: Article

References (25)

1. Riggi, N.; Stamenkovic, I. The biology of Ewing sarcoma. Cancer Lett. 254:1-10; 2007.
2. Rodriguez-Galindo, C.; Spunt, S. L.; Pappo, A. S. Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Med. Pediatr. Oncol. 40:276-287; 2003.
3. Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:4368-4380; 2002.
4. Lee, T. H.; Bolontrade, M. F.; Worth, L. L.; Guan, H.; Ellis, L. M.; Kleinerman, E. S. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int. J. Cancer 119:839-846; 2006.
5. Guan, H.; Zhou, Z.; Wang, H.; Jia, S. F.; Liu, W.; Kleinerman, E. S. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin. Cancer Res. 11:2662-2669; 2005.
6. Henriksen, K.; Karsdal, M.; Delaisse, J. M.; Engsig, M. T. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J. Biol. Chem. 278:48745-48753; 2003.
7. Nakagawa, M.; Kaneda, T.; Arakawa, T.; Morita, S.; Sato, T.; Yomada, T.; Hanada, K.; Kumegawa, M.; Hakeda, Y. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett. 473:161-164; 2000.
8. Niida, S.; Kondo, T.; Hiratsuka, S.; Hayashi, S.; Amizuka, N.; Noda, T.; Ikeda, K.; Shibuya, M. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc. Natl. Acad. Sci. USA 102:14016-14021; 2005.
9. Iguchi, H.; Yokota, M.; Fukutomi, M.; Uchimura, K.; Yonemasu, H.; Hachitanda, Y.; Nakao, Y.; Tanaka, Y.; Sumii, T.; Funakoshi, A. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 21:309-313; 2002.
10. Kumta, S. M.; Huang, L.; Cheng, Y. Y.; Chow, L. T.; Lee, K. M.; Zheng, M. H. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 73:1427-1436; 2003.
11. Lacey, D. L.; Timms, E.; Tan, H. L.; Kelley, M. J.; Dunstan, C. R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; Hsu, H.; Sullivan, J.; Hawkins, N.; Davy, E.; Capparelli, C.; Eli, A.; Qian, Y. X.; Kaufman, S.; Sarosi, I.; Shalhoub, V.; Senaldi, G.; Guo, J.; Delaney, J.; Boyle, W. J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176; 1998.
12. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K.; Udagawa, N.; Takahashi, N.; Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/ RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602; 1998.
13. Weitzmann, M. N.; Cenci, S.; Rifas, L.; Haug, J.; Dipersio, J.; Pacifici, R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J. Bone Miner. Res. 16:328-337; 2001.
14. Zhang, J.; Dai, J.; Qi, Y.; Lin, D. L.; Smith, P.; Strayhorn, C.; Mizokami, A.; Fu, Z.; Westman, J.; Keller, E. T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107:1235-1244; 2001.
15. Tropel, P.; Noel, D.; Platet, N.; Legrand, P.; Benabid, A. L.; Berger, F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp. Cell Res. 295:395-406; 2004.
16. Holzer, G.; Obermair, A.; Koschat, M.; Preyer, O.; Kotz, R.; Trieb, K. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med. Pediatr. Oncol. 36:601-604; 2001.
17. Aldridge, S. E.; Lennard, T. W.; Williams, J. R.; Birch, M. A. Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 335:793-798; 2005.
18. Peyruchaud, O.; Serre, C. M.; NicAmhlaoibh, R.; Fournier, P.; Clezardin, P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J. Biol. Chem. 278:45826-45832; 2003.
19. Zhou, Z.; Reddy, K.; Guan, H.; Kleinerman, E. S. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol. Cancer Res. 5:1125-1132; 2007.
20. Ren, W. P.; Markel, D. C.; Zhang, R.; Peng, X.; Wu, B.; Monica, H.; Wooley, P. H. Association between UHMWPE particle-induced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials 27:5161-5169; 2006.
21. Kodama, I.; Niida, S.; Sanada, M.; Yoshiko, Y.; Tsuda, M.; Maeda, N.; Ohama, K. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. J. Bone Miner. Res. 19:200-206; 2004.
22. Akiyama, H.; Mohamedali, K. A.; Kachi, S.; Shen, J.; Hatara, C.; Umeda, N.; Hackett, S. F.; Aslam, S.; Krause, M.; Lai, H.; Rosenblum, M. G.; Campochiaro, P. A. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol. Pharmacol. 68:1543-1550; 2005.
23. Dougall, W. C.; Chaisson, M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25:541-549; 2006.
24. Lau, Y. S.; Adamopoulos, I. E.; Sabokbar, A.; Giele, H.; Gibbons, C. L.; Athanasou, N. A. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br. J. Cancer 96:1716-1722; 2007.
25. Fuchs, B.; Inwards, C. Y.; Janknecht, R. Vascular endothelial growth factor expression is up-regulated by EWSETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin. Cancer Res. 10:1344-1353; 2004.